WO2003004646A3 - Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors - Google Patents

Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors Download PDF

Info

Publication number
WO2003004646A3
WO2003004646A3 PCT/IB2002/003866 IB0203866W WO03004646A3 WO 2003004646 A3 WO2003004646 A3 WO 2003004646A3 IB 0203866 W IB0203866 W IB 0203866W WO 03004646 A3 WO03004646 A3 WO 03004646A3
Authority
WO
WIPO (PCT)
Prior art keywords
patches
delivery
cells
methods
peyers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2002/003866
Other languages
French (fr)
Other versions
WO2003004646A2 (en
Inventor
Daniel J O'mahony
Daragh Byrne
David Brayden
Imelda Lambkin
Lisa Higgins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Corp PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Priority to EP02777590A priority Critical patent/EP1419252A2/en
Priority to CA002443644A priority patent/CA2443644A1/en
Publication of WO2003004646A2 publication Critical patent/WO2003004646A2/en
Anticipated expiration legal-status Critical
Publication of WO2003004646A3 publication Critical patent/WO2003004646A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Methods of increasing of or decreasing the levels of a protein in a PP cell; methods of increasing antigen, vaccine, DNA vaccine delivery to M cells, use of human serum albumin and other transport enhancing proteins to enhance oral drug delivery; use of calreticulin to enhance oral antigen delivery, use of other cell surface proteins, receptors, and transporters to enhance delivery to M cells of antigens or vaccine delivery vehicles, use of other cytoplasmic proteins to regulate intracellular trafficking and delivery to mucosal immune sampling and processing systems.
PCT/IB2002/003866 2001-04-04 2002-04-04 Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors Ceased WO2003004646A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02777590A EP1419252A2 (en) 2001-04-04 2002-04-04 Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
CA002443644A CA2443644A1 (en) 2001-04-04 2002-04-04 Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28138701P 2001-04-04 2001-04-04
US60/281,387 2001-04-04
US30259101P 2001-07-02 2001-07-02
US60/302,591 2001-07-02

Publications (2)

Publication Number Publication Date
WO2003004646A2 WO2003004646A2 (en) 2003-01-16
WO2003004646A3 true WO2003004646A3 (en) 2004-03-11

Family

ID=26960864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/003866 Ceased WO2003004646A2 (en) 2001-04-04 2002-04-04 Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors

Country Status (4)

Country Link
US (1) US20030211476A1 (en)
EP (1) EP1419252A2 (en)
CA (1) CA2443644A1 (en)
WO (1) WO2003004646A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60229867D1 (en) * 2001-07-02 2008-12-24 Merrion Res Iii Ltd TARGETED LIGANDS AGAINST PEYER'S FLAKE AND / OR M CELLS
EP1721977A3 (en) * 2001-09-17 2008-10-15 PDL BioPharma, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA2518552A1 (en) * 2003-03-11 2004-09-23 Genentech, Inc. Novel compositions and methods for the treatment of immune related disease
GB0313132D0 (en) * 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
ES2543341T3 (en) 2005-09-13 2015-08-18 National Research Council Of Canada Methods and compositions to modulate the activity of tumor cells
US20100087005A1 (en) * 2006-10-10 2010-04-08 Chiaki Hidai Auxiliary reagent for gene transfer
AU2007202629A1 (en) * 2007-06-08 2009-01-08 Ian Andrew Ferguson Nasal-administered vaccines
EA034462B1 (en) 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9822170B2 (en) 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6117632A (en) * 1995-11-10 2000-09-12 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
WO2002080852A2 (en) * 2001-04-04 2002-10-17 Digital Gene Technologies, Inc. Genes expressed in intestinal epithelium and peyer's patch m cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203291A (en) * 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
US5171578A (en) * 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5047245A (en) * 1985-07-26 1991-09-10 The Liposome Company, Inc. Novel composition for targeting, storing and loading of liposomes
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
US5254342A (en) * 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5552155A (en) * 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
HUP0000522A3 (en) * 1996-10-15 2000-10-30 Transave Inc Monmouth Junction N-acyl phoshpatidylethanolamine-mediated liposomal drug delivery
EP0964690B1 (en) * 1996-10-15 2003-07-09 The Liposome Company, Inc. Peptide-lipid conjugates, liposomes and liposomal drug delivery

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117632A (en) * 1995-11-10 2000-09-12 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
WO2002080852A2 (en) * 2001-04-04 2002-10-17 Digital Gene Technologies, Inc. Genes expressed in intestinal epithelium and peyer's patch m cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GULLBERG ELISABET ET AL: "Expression of specific markers and particle transport in a new human intestinal M-cell model.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 279, no. 3, 29 December 2000 (2000-12-29), pages 808 - 813, XP002252802, ISSN: 0006-291X *
HADDAD A ET AL: "TARGETED M CELL IMMUNIZATION FOR HIV-1 ENV DNA VACCINES", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 14, no. 6, 20 April 2000 (2000-04-20), pages A1204, XP000995418, ISSN: 0892-6638 *

Also Published As

Publication number Publication date
EP1419252A2 (en) 2004-05-19
WO2003004646A2 (en) 2003-01-16
CA2443644A1 (en) 2003-01-16
US20030211476A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
WO2003004646A3 (en) Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
WO2001026608A3 (en) Dna vaccines encoding antigen linked to a domain that binds cd40
WO2003076603A3 (en) Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
WO2002061113A3 (en) Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
WO2001098335A3 (en) Transgenic algae for delivering antigens to an animal
IL169313A0 (en) Immunotherapy of b cell malignancies and autoimmune disease using nuconjugated antibodies and conjugated antibodies, antibody combinations and fusion proteins
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
EP3611270B1 (en) Kits for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs
AU2003216289A1 (en) Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, dna and viruses
IL161832A0 (en) Pharmaceutical composition for inducing an immune response in a human or animal
SG160424A1 (en) Compositions of influenza viral proteins and methods of use thereof
WO1999063945A3 (en) Vaccination strategy to prevent and treat cancers
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
WO2005007673A3 (en) Immunogenic peptides
GB0318096D0 (en) Vaccine
WO2003066820A3 (en) Nucleic acid molecules encoding cd1-derived endosomal targeting proteins and uses thereof
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
WO2007053188A3 (en) Production of multivalent virus like particles
GB0113798D0 (en) Antigens and vectors for vaccination
WO2009014404A3 (en) Multifunctional protein simultaneously delivering antibodies and nanoparticles
WO2004027036A3 (en) Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
WO2005000884A8 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
JP2004513879A5 (en)
WO2003037370A3 (en) Anthrax antigenic compositions
SE9604470D0 (en) Transmembrane component of tight junction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2443644

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002777590

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002777590

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002777590

Country of ref document: EP